I 'm familiar with Paion. I admire the Soehngens for having had the cojones to build a stroke company when almost all pharma firms were running the other way. The ultimate Pharma contrarians. Both Paion's DSPA and NTI's Viprinex have had bleeding problems in the past--it does look like Paion has been able to change the regimen to avoid that, and perhaps NTI has as well. Paion was particularly smart to use imaging to make sure there was a penumbra to be salvaged, a real advantage in their trial, which NTI is not doing.
<< Desmoteplase(plasminogen activator) and Enecadin(neuroprotectant) combination which is reco by intl stroke experts. Smart choice which RNVS doesn't have>
I'm not sure I follow that....Enecadin is in Phase IIa, and until it shows human proof of principle, it remains in that chorus line of so many stroke drugs which have done so much....for occluded rodents....Will combining sodium and calcium channel blockage 'en suite' work for humans? Could be. Paion would be in great shape IF DSPA is approved and....Enecadin follows suit in 2012-13, they would own the best cocktail for stroke.... But any neuroprotectant can be combined with a thrombolytic, so in the meantime, IF NXY-059 passes muster, it will be often be given with tPA (indeed, it may expand the usability of tPA) for now, with DSPA and/or Viprinex later....
Harry
NeuroInvestment |
